Additional file 1 of A novel lncRNA ARST represses glioma progression by inhibiting ALDOA-mediated actin cytoskeleton integrity

Additional file 1: Figure S1. (A) The expressions of LINC00632 in normal people (left) and glioma patients (right) based on the TCGA database. (B) The differential expression levels of LINC00632 are displayed in different tumors compared with the respective normal tissues. (C) Graphic representation of relative LINC00632 expression level (TPM) in different tissues (GBM vs. GTEx, LGG vs. GTEx). GBM and LGG represented glioblastoma multiforme and low grade gliomas in the TCGA datasets. GTEx represented normal brain tissue in the GTEx database. (D) Transcripts per million (TPM) of LINC00632 in different cancers according to the TCGA database. GBM and LGG are highlighted in green (downregulated). (E) Overall and (F) disease free survivals of the glioma patients with relative low or high level of LINC00632 expressions were assessed in the GEPIA database (cut-off value is 50%). (G) Fluorescence in situ hybridization (FISH) assay was performed to detect the location of ARST in the U251 cells. Human 18S was used as a cytoplasm internal control and human U6 was used as a nucleus internal control. Proportions of ARST and the internal controls were determined in the cytoplasm and nucleus of the cells. Scale bar = 5 μm.